Abstracts Archive - Page 1996 of 2425 - ACR Meeting Abstracts

Abstract Number: 829 • 2014 ACR/ARHP Annual Meeting
Asymptomatic Deposit of Monosodium Urate Crystals Associates to a More Severe Coronary Calcification in Hyperuricemic Patients with Acute Coronary Syndrome
Mariano Andrés¹, María Amparo Quintanilla², Francisca Sivera¹, Paloma Vela^3,4 and Juan Miguel Ruiz-Nodar⁵, ¹Sección de Reumatología, Hospital General Universitario de Elda, Alicante, Spain, ²Sección de Cardiología, Hospital General Universitario de Elda, Alicante, Spain, ³Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain, ⁴Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, ⁵Servicio de Cardiología, Hospital General Universitario de Alicante, Alicante, Spain
Background/Purpose: Increased cardiovascular (CV) risk in gout relates to crystal-driven inflammation. Monosodium urate (MSU) crystals are found in ~25% of patients with asymptomatic hyperuricemia (AH)…
Abstract Number: 828 • 2014 ACR/ARHP Annual Meeting
Extent of Urate Deposition in Asymptomatic Hyperuricemia and Symptomatic Gout: A Dual Energy Computed Tomography Study
Nicola Dalbeth¹, Meaghan House¹, Opetaia Aati¹, Paul Tan², Christopher Franklin², Anne Horne¹, Gregory Gamble¹, Lisa K. Stamp³, Anthony Doyle² and Fiona M. McQueen⁴, ¹Department of Medicine, University of Auckland, Auckland, New Zealand, ²University of Auckland, Auckland, New Zealand, ³University of Otago, Christchurch, New Zealand, ⁴Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand
Background/Purpose: Recent studies have reported that ultrasound features of urate crystal deposition are present in some asymptomatic individuals with hyperuricemia, suggesting that subclinical urate deposition…
Abstract Number: 827 • 2014 ACR/ARHP Annual Meeting
Gout and the Risk of Alzheimer’s Disease: A Population-Based Cohort Study
Na Lu¹, Yuqing Zhang¹, Alberto Ascherio², Miguel Hernan², Tuhina Neogi¹, Maureen Dubreuil^3,4 and Hyon K. Choi⁵, ¹Boston University School of Medicine, Boston, MA, ²Epidemiology, Harvard School of Public Health, Boston, MA, ³Rheumatology, Boston University Medical Center, Boston, MA, ⁴Rheumatology, Boston VA HealthCare System, Boston, MA, ⁵Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: While gout is associated with cardiovascular (CV)-metabolic comorbidities and their sequelae, uric acid's anti-oxidant effects may have neuroprotective benefits. Several studies have found an…
Abstract Number: 826 • 2014 ACR/ARHP Annual Meeting
Comparison of Classification Criteria for Gout Using Monosodium Urate Crystal Identification By a Certified Examiner As the Gold-Standard in a Large Multi-National Study
William Taylor¹, Nicola Dalbeth², Jaap Fransen³, Tuhina Neogi⁴, H. Ralph Schumacher Jr.⁵ and Tim Jansen⁶, ¹Department of Medicine, University of Otago Wellington, Wellington, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Radboud University, Nijmegen, Netherlands, ⁴Boston University School of Medicine, Boston, MA, ⁵University of Pennsylvania VA Medical Center, Philadelphia, PA, ⁶Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: Most gout is managed in primary care where the diagnosis seldom relies upon identification of MSU crystals. Several classification criteria for gout have been…
Abstract Number: 824 • 2014 ACR/ARHP Annual Meeting
Impact of Oral Glucocorticoid Therapy on Mortality in Patients with Rheumatoid Arthritis and Diabetic Mellitus
Mohammad Movahedi and William G Dixon, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose Glucocorticoid (GC) therapy is known to increase the risk of new-onset type 2 diabetes mellitus (DM). Furthermore, GC therapy increases blood glucose in diabetic…
Abstract Number: 825 • 2014 ACR/ARHP Annual Meeting
Serious Infections on TNF Inhibitors: Have the Risks Changed over Calendar Time, and How High Are They?
Elizabeth V. Arkema¹, Johan Askling² and the ARTIS Study group³, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ³Karolinska Institutet och Svensk Reumatologisk förening, Solna, Sweden
Background/Purpose: The rheumatoid arthritis (RA) population starting tumor necrosis factor inhibitors (TNFi) today is much different in terms of accumulated and concurrent disease activity and…
Abstract Number: 823 • 2014 ACR/ARHP Annual Meeting
Risk of Active Tuberculosis in Patients with Arthritis Receiving TNF-α Inhibitors: A Look Beyond the Baseline Tuberculosis Screening Protocol
Alina Soare¹, Carina Mihai², Ana Maria Gherghe², Rucsandra Dobrota², Raida Oneata², Simona Pintilie², Mihaela Milicescu², Ioan Ancuta², Andrei Martin², Mariana Sasu², Claudia Ciofu², Liviu Macovei², Victor Stoica² and Mihai Bojinca², ¹internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy & Cantacuzino Hospital, Bucharest, Romania, ²Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy & Cantacuzino Hospital, Bucharest, Romania
Background/Purpose Tuberculosis (TB) is a major concern in patients receiving TNF inhibitors (TNFi), especially in countries with a high TB burden. Careful TB screening is…
Abstract Number: 822 • 2014 ACR/ARHP Annual Meeting
Meloxicam and Risk of Myocardial Infarction: A Population-Based Cohort Study
Deepan Dalal¹, Maureen Dubreuil^2,3, Yuqing Zhang⁴, Christine Peloquin⁵, Tuhina Neogi⁴, Hyon K. Choi² and David T. Felson⁶, ¹Rheumatology, Boston Medical Center, Boston, MA, ²Rheumatology, Boston University School of Medicine, Boston, MA, ³Rheumatology, VA Boston Healthcare System, Jamaica Plain, MA, ⁴Boston University School of Medicine, Boston, MA, ⁵Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA, ⁶Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Certain non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with an increased risk of myocardial infarction (MI). MI risk for different NSAIDs varies largely because…
Abstract Number: 821 • 2014 ACR/ARHP Annual Meeting
Pregnancy Outcome in Women Treated with Adalimumab for the Treatment of Rheumatoid Arthritis: An Update
Christina D Chambers^1,2, Diana L Johnson¹, Yunjun Luo¹, Ronghui Xu^2,3 and Kenneth L Jones¹, ¹University of California San Diego Department of Pediatrics, La Jolla, CA, ²University of California San Diego Department of Family and Preventive Medicine, La Jolla, CA, ³University of California San Diego Department of Mathematics, La Jolla, CA
Background/Purpose Adalimumab is a fully human monoclonal antibody to tumor necrosis factor alpha and is approved for several indications including rheumatoid arthritis (RA). Methods The…
Abstract Number: 820 • 2014 ACR/ARHP Annual Meeting
Herpes Zoster Infection Risk in Auto-Immune and Inflammatory Diseases: Implications for Vaccination
Huifeng Yun¹, Shuo Yang², Lang Chen³, Fenglong Xie⁴, Kevin L. Winthrop⁵, John Baddley³, Kenneth G. Saag⁶, Jasvinder A. Singh⁷ and Jeffrey R. Curtis⁸, ¹Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁵Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, ⁶Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Herpes zoster (HZ) vaccine is recommended for healthy people age >= 60 years in US. It is unclear whether the absolute risk for younger…
Abstract Number: 839 • 2014 ACR/ARHP Annual Meeting
Cardiovascular Risk with Nsaids in Rheumatoid Arthritis: An Analysis Using Routinely Collected Data
Fowzia Ibrahim¹, Antigoni Grigoriou^1,2, Khaldoun Chaabo^1,2, David L. Scott^1,2, Sophia Steer^1,2 and James Galloway^1,2, ¹King's College London, Department of Rheumatology, London, United Kingdom, ²King's College Hospital, Department of Rheumatology, London, London, United Kingdom
Background/Purpose Atherosclerotic disease increases the morbidity and mortality in Rheumatoid Arthritis (RA). NSAIDs are associated with Cardiovascular (CV) risk in the general population. Data from…
Abstract Number: 838 • 2014 ACR/ARHP Annual Meeting
The Impact of Rheumatoid Arthritis Disease Activity on Cardiovascular Disease Risk: What Is the Role of the Flare?
Elena Myasoedova¹, Arun K. Chandran², Birkan İlhan³, Brittny T. Major⁴, C. John Michet III², Eric L. Matteson² and Cynthia S. Crowson⁴, ¹Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey, ⁴Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease (CVD). Longitudinal studies assessing the effect of changes of RA activity on…
Abstract Number: 837 • 2014 ACR/ARHP Annual Meeting
Progressive Multifocal Leukoencephalopathy Associated with Biologic Therapy in Rheumatic Diseases: Strengthening Association with Rituximab
Eamonn Molloy¹ and Leonard H. Calabrese², ¹St Vincent University Hospital, Dublin, Ireland, ²Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose Progressive Multifocal Leukoencephalopathy (PML) is a rare and often fatal opportunistic infection recently associated with several biologic therapies. However, ascribing risk to individual therapies…
Abstract Number: 836 • 2014 ACR/ARHP Annual Meeting
Categorical Change in 6MWD in Patients with Connective Tissue Disease Associated Pulmonary Arterial Hypertension Receiving Ambrisentan over 3-Years
Aryeh Fischer¹, Virginia D. Steen², Steven Nathan³, Hunter Gillies⁴, James Tislow⁵ and Chris Blair⁶, ¹Rheumatology / ILD Program, National Jewish Health, Denver, CO, ²Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ³Heart Failure/Transplant, Inova Medical Group, Falls Church, VA, ⁴Clinical Research - Cardiovascular, Gilead Sciences, Inc., Foster City, CA, ⁵Medical Affairs, Gilead Sciences, Inc., Foster City, CA, ⁶Biostatistics, Gilead Sciences, Inc., Foster City, CA
Background/Purpose: The 6MWD is a valuable tool for evaluating response to therapy in patients with pulmonary arterial hypertension and may be considered a surrogate measure…
Abstract Number: 835 • 2014 ACR/ARHP Annual Meeting
Relapsing Polychondritis Can be Characterized By 3 Different Clinical Phenotypes: Analysis of a Series of 142 Patients
Jeremie Dion¹, Nathalie Costedoat-Chalumeau¹, Damien Sène², Judith Cohen-Bittan³, Gaëlle Leroux⁴, Charlotte Dion⁵, Camille Francès⁶ and Jean-Charles Piette⁷, ¹Internal medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ²Hopital Lariboisière, service de Médecine Interne, Paris, France, ³Service de medecine gériatrique, CHU Pitié-Salpêtrière, Paris, France, ⁴Department of Internal Medicine 1, CHU Pitié-Salpêtrière, Paris, France, ⁵Ecole des hautes études en sciences sociales, Paris, France, ⁶service de dermatologie allergologie, Hôpital Tenon, Paris Cedex 20, France, ⁷Department of Internal Medicine 1., CHU Pitié-Salpêtrière, Paris, France
Background/Purpose We previously described clinical characteristics and evolution of 142 patients with relapsing polychondritis (RP) followed in a single center and seen at least once…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].